Psoriasis is associated with numerous comorbid conditions, including psoriatic arthritis, metabolic syndrome, and cardiovascular disease, which often share a similar pathogenesis and follow a progressive pattern. Biologic agents, specifically those targeting tumor necrosis factor, constitute a relatively new, effective, and safe treatment modality for this disease. Because these agents are effective in suppressing the inflammation that occurs in psoriasis, they appear to play a key, but somewhat novel, role in preventing some comorbidities. This review article attempts to elucidate this concept through the currently available literature. We evaluate the possible effects of tumor necrosis factor antagonists on the natural history of psoriasis comorbidities in an effort to shed some light on this exciting frontier.
PierardG., Pierard-FranchimontC., SzepetiukG., PaquetP., QuatresoozP.The therapeutic potential of TNF-a antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther.2010; 20(8) 1197–208.
2.
GelfandJ.M., NeimannA.L., ShinD.B., WangX., MargolisD.J., TroxelA.B.Risk of myocardial infarction in patients with psoriasis. JAMA2006; 296(14): 1735–41.
3.
AlsufyaniM., GolantA., LebwohlM.Psoriasis and the metabolic syndrome. Dermatol Ther.2010; 23: 137–43.
4.
VenaG., VestitaM., CassanoN.Can early treatment with biologicals modify the natural history of comorbidities?Dermatol Ther2010; 23: 181–93.
5.
National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. NIH Publication No. 02-5215, 2002.
6.
VenaG., VestitaM., CassanoN.Psoriasis and cardiovascular diseaseDermatolog Ther.2010; 23: 144–51.
7.
GisondiP., GirolomoniG.Psoriasis and atherothrombotic diseases disease-specific and non-disease-specific risk factors. Semin Thromb Hemost.2009; 35: 313–24.
8.
MalikS., WongN.D., FranklinS., PioJ., FairchildC., ChenR.Cardiovascular disease in US patients with metabolic syndrome, diabetes and elevated C-reactive protein. Diabetes Care.2005; 28: 690–3.
9.
TamL.S., TomlinsonB., ChuT.T.W.Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology.2008; 47: 718–23.
10.
MallbrisL., AkreO., GranathF.Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol2004; 19: 225–30.
11.
KremersH.M., McEvoyM.T., DannF.J., GabrielS.E.Heart disease in psoriasis. J Am Acad Dermatol.2007; 57: 347–54.
12.
JacobssonL., TuressonC., NilssonJ.Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis.2007; 66: 670–5.
13.
PreyS., PaulC., BronsardV.Cardiovascular risk factors in patients with plaque psoriasis: a systemic review of epidemiological studies. J Eur Acad Dermatol Venereol.2010; 24(suppl 2): 23–30.
14.
DixonW.G., SymmonsD.P.M.What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann Rheum Dis.2007; 66: 1132–6.
15.
HernandezC., CetnerA., JordanE., PuangsuvanS., RobinsonJ.Tuberculosis in the age of biologic therapy. J Am Acad Dermatol2008; 59: 363–80.
16.
VenaG., VestitaM., CassanoN.Can early treatment with biologicals modify the natural history of comorbidities?Dermatol Ther2010; 23: 181–93.
17.
AllanoreY., KahanA., SellamJ., EkindjianO.G., BorderieD.Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta.2006; 365: 143–8.
18.
PopaC., NeteaM.G., RadstakeT.Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis.2005; 64: 303–5.
19.
SpanakisE., SidiropoulosP., PapadakisJ.Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with Infliximab. J Rheumatol2006; 33: 2330–446.
20.
CauzaE., CauzaK., Hanusch-EnsererU., EtemadM., DunkyA., KostnerK.Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr.2002; 114: 1004–7.
21.
DahlqvistS.R., EngstrandS., BerglinE., JohnsonO.Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol.2006: 35107–11.
22.
MarraM., CampanatiA., TestaR.Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol.2007; 20: 731–6.
23.
KiotsisD.N., MavridisA.K., VasakosS., NikasS.N., DrososA.A.Effects of infliximab on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis.2005; 64: 765–6.
24.
HuversF.C., PopaC., NeteaM.G., Van den HoogenF.H., TackC.J.Improved insulin sensitivity by anti-TNF alpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis.2007; 66: 558–9.
25.
KiortsisD.N., MavridisA.K., VasakosS., NikasS.N., DrososA.A.Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis.2005; 64: 765–6.
26.
SaracenoR., SchipaniC., MazzottaA.Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res.2008; 57: 290–5.
27.
GisondiP., CotenaC., TessariG., GirolomoniG.Anti-tumor necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol.2008; 22: 341–4.
28.
MarcoraS.M., ShesterK.R., MittalG., LemmeyA.B., MaddisonP.J.Randomized phase 2 trial of anti-tumor necrosis therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr.2006; 84: 1463–72.
29.
BernsteinL.E., BerryJ., KimS., CanavanB., GrinspoonS.K.Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med2006; 166: 902–8.
30.
StroberB., TellerC., YamauchiP.Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol.2008; 159: 322–30.
31.
KerekesG., SolteszP., DerH.Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis contemporary challenges in autoimmunity. Ann NY Acad Sci.2009; 1173: 814–21.
32.
SidiropoulosP.I., SiakkaP., PagonidisK.Sustained improvement of vascular endothelial function during anti-TNFa treatment in rheumatoid arthritis patients. Scand J Rheumatol.2009; 38: 6–10.
33.
ListingJ., StrangfeldA., KekowJ.Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?Arthritis Rheum.2008; 58: 667–77.
34.
DixonW.G., WatsonK.D., LuntM., HyrichK.L.Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum.2006; 54: 3790–8.
35.
StroberB.E., MenonK.Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol.2005; 53: 652–9.
36.
JacobssonJ., TuressonC., GulfeA.Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol.2005; 32: 1213–8.
37.
ChungE.S., PackerM., LoK.H., FasanmadeA.A., WillersonJ.T.Randomized double-blind, placebo-controlled, pilot trial of infliximab a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate to severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation2003; 107: 3133–40.
38.
ColeJ., BustiA., KaziS.The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int.2007; 27: 369–73.
